See How it’s Done: Case Studies on Patient Experience Design

Designing clinical trials around the patient and their experience produces better trials, but what does that really mean, and how is it actually accomplished? How can you be sure you’re collecting data of interest to patient communities? Many common strategies have minimal impact or inadvertently create new challenges for patients. If the trial doesn’t work for patients in their everyday lives, then no recruitment or retention plan can guarantee your study will generate the data you need.

In this webinar, you’ll hear from experts dedicated to creating accessible studies that capture the data sponsors need to move to the next stage in product development. Hear from clinical development professionals who have worked with sponsors across therapeutic areas, phases, and modalities to dig into the details of their protocols, examine their application, and ultimately design trials that work for diverse patients. They’ll be joined by a patient advocate who recently collected extensive patient and researcher community data that will be used to inform clinical development for GLUT1 deficiency syndrome. Together, they’ll dive into real-world examples from their work that you can apply to your program, showing how to de-risk your protocol and truly design your trial with the patient in mind.

In this webinar, you’ll learn how to:

• Design trials with a patient experience approach
• Consider data that is important to patient communities
• Examine a protocol for patient experience optimization
• Apply real-life examples to your study

Speakers

Daniel A. Perez, CCRP, Global Head of Patient Experience, Diversity & Inclusion, Worldwide Clinical Trials

Daniel A. Perez has worked in healthcare and the pharmaceutical industry for over 14 years, moving through various progressive roles in health administration, clinical operations, strategic business development, and C-Suite executive management. To date, he has led the implementation of over 40 early and late phase clinical trials, overseeing full cycle including protocol development, protocol feasibility, site qualification, site initiation/study start-up, clinical operations, patient recruitment & retention, standard operating procedure & policy writing, and regulatory strategy.

Message Presenter

Juliane K. Mills, MS, MPH, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials

Juliane K. Mills has worked in clinical research for more than 23 years, providing significant scientific and strategic design input as a subject matter expert for Phase I-IV rare disease trials and real-world studies. At Worldwide, Juliane provides operational strategies that are efficient and effective for delivering rare disease trials while being accessible to patients, caregivers, and families. She also leverages her experience supporting product registries, retrospective chart reviews, health economics and outcomes research (HEOR) studies, and compassionate use/expanded access programs. Juliane has held positions on both the sponsor and CRO side of clinical development, providing operational services and developing trial and patient-facing materials in various therapeutic areas.

Message Presenter

Sandra Ojeda, Science Director, Glut1 Deficiency Foundation

Sandra Ojeda holds a BS in Microbiology from Universidad de los Andes in Colombia, a MS in Biochemistry and Molecular Biology from Universitat Autonoma de Barcelona in Spain and a PhD in Microbiology and Immunology from UT Health Science Center in San Antonio. She has worked on cancer research at MD Anderson Cancer Center and more recently, she has taught science at a private school and worked at her daughter’s elementary school. Sandra and her family, husband Juan Manuel and daughter Sofia Mar, have lived in Katy, Texas since 2006. Sofia Mar was diagnosed with Glut1 Deficiency in 2012 at age 3 at Texas Children’s Hospital in Houston.

Message Presenter